Celgene terminates Revlimid ORIGIN trial for CLL
Celgene Corporation has announced that after consultation with the FDA Celgene will discontinue treatment with Revlimid (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries. An imbalance was observed in the number of deaths in patients treated with lenalidomide versus patients treated with chlorambucil.
The FDA placed the ORIGIN study on clinical hold on July 12, 2013, with the discontinuation of lenalidomide treatment. All clinical investigators in ongoing Chronic Lymphocytic Leukemia studies using lenalidomide will be officially advised of this action and instructed to inform their patients accordingly. Revlimid is not approved as a treatment for patients with Chronic Lymphocytic Leukemia.
All other Celgene-sponsored Chronic Lymphocytic Leukemia clinical trials with lenalidomide are continuing in accordance with their respective protocols.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.